CoChat
Sign Up
Cited by 129Attention Deficit Hyperactivity DisorderPharmaceutical studies and practicesBehavioral and Psychological Studies

Evolution of the treatment of attention-deficit/hyperactivity disorder in children: A review

Findling, Robert L.·2008·Clinical Therapeutics
DOI 10.1016/j.clinthera.2008.05.006
Open this paper in CoChat — free account

Abstract

Background Efficacious and well-tolerated medications are available for the treatment of attention-deficit/hyperactivity disorder (ADHD). Stimulants such as methylphenidate (MPH) and amphetamines are the most widely used medications approved by the US Food and Drug Administration for the treatment of ADHDin children. Objective This article reviews the literature on the development and use of medications for the treatment of ADHD in children. Methods A search of MEDLINE was conducted toidentify relevant studies and critical reviews on the treatment of ADHD in children. The main criteria for inclusion of a study were that it have a controlled design, enroll >100 subjects if a clinical trial and >20 subjects if a classroom study, assess symptoms with the most widely used scales and tests,and be published from 2000 to 2008.A few older pivotal studies were also included. Results Many studies have reported the long-term efficacy and tolerability of immediate-release formulations of MPH. The disadvantages of such formulations include the need for multiple daily dosing and a potential for abuse. Various extended-release formulations of MPH have been found effective in controlled studies enrolling large numbers of children with ADHD. The efficacy and tolerability of dexmethylphenidate, the active D-isomer of MPH, in an extended-release formulation have also been reported. An extended-release formulation of mixed amphetamine salts (MMAS-XR) that is dosed once daily has been found to be…

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2008.05.006

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Randomized controlled trials indicate that ADHD medication improves ADHD symptoms in the short term.

    “Randomized controlled studies suggest that ADHD medication have beneficial short-term effects on symptoms of ADHD (Adler et al., 2009; Banaschewski et al., 2006; Findling, 2008; Findling et al., 2008; Koesters, Becker, Kilian, Fegert, & Weinmann, 2009; Kooij et al., 2010; Newcorn et al., 2008; Svanborg et al., 2009; Young, Sarkis, Qiao, & Wietecha, 2011).”

    From Stimulant <scp>ADHD</scp> medication and risk for substance abuse (2014) · cites this paper as Findling, 2008

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Findling, R. L.
Affiliations
University Hospitals Cleveland Medical Center (US)
Corresponding author
Findling, Robert L.
ORCID
Findling, Robert L.
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2008-05
Volume
30
Issue
5
Pages
942-957
ISSN
0149-2918 (ISSN-L)
DOI
10.1016/j.clinthera.2008.05.006
OpenAlex
W2101112582
Cited by
129
References
7
Citations by year
2025: 1 · 2023: 3 · 2022: 4 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 4 · 2016: 14 · 2015: 11 · 2014: 8 · 2013: 15 · 2012: 17
FWCI
1.46
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinical Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmaceutical studies and practices
  • Social Sciences › Psychology › Developmental and Educational Psychology › Behavioral and Psychological Studies
Keywords
attention deficit hyperactivity disorder, children, stimulant medication, methylphenidate, sustained-release formulation, dexmethylphenidate, mixed amphetamine salts, atomoxetine, lisdexamfetamine dimesylate, non-stimulant medication, drug tolerability, abuse liability, long-term efficacy, pharmacokinetic variability
MeSH terms
Atomoxetine Hydrochloride, Amphetamines, Central Nervous System Stimulants, Attention Deficit Disorder with Hyperactivity, Child, Humans, Methylphenidate, Prodrugs, Propylamines, Norepinephrine Plasma Membrane Transport Proteins, Dexmethylphenidate Hydrochloride

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review